210 related articles for article (PubMed ID: 10853618)
1. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis.
Matzke GR; Frye RF; Joy MS; Palevsky PM
Pharmacotherapy; 2000 Jun; 20(6):635-43. PubMed ID: 10853618
[TBL] [Abstract][Full Text] [Related]
2. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.
Joy MS; Matzke GR; Frye RF; Palevsky PM
Am J Kidney Dis; 1998 Jun; 31(6):1019-27. PubMed ID: 9631848
[TBL] [Abstract][Full Text] [Related]
3. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.
Matzke GR; Frye RF; Joy MS; Palevsky PM
Antimicrob Agents Chemother; 2000 Jun; 44(6):1639-44. PubMed ID: 10817721
[TBL] [Abstract][Full Text] [Related]
4. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem clearance during modeled continuous renal replacement therapy.
Stevenson JM; Patel JH; Churchwell MD; Vilay AM; Depestel DD; Sörgel F; Kinzig M; Jakob V; Mueller BA
Int J Artif Organs; 2008 Dec; 31(12):1027-34. PubMed ID: 19115194
[TBL] [Abstract][Full Text] [Related]
8. Comparison of solute clearance in three modes of continuous renal replacement therapy.
Parakininkas D; Greenbaum LA
Pediatr Crit Care Med; 2004 May; 5(3):269-74. PubMed ID: 15115566
[TBL] [Abstract][Full Text] [Related]
9. Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters.
Kandus A; Ponikvar R; Drinovec J; Pavlin K; Ivanovich P
Int J Artif Organs; 1990 Apr; 13(4):200-4. PubMed ID: 2197235
[TBL] [Abstract][Full Text] [Related]
10. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.
Patel JH; Churchwell MD; Seroogy JD; Barriere SL; Grio M; Mueller B
Int J Artif Organs; 2009 Oct; 32(10):745-51. PubMed ID: 19943236
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration.
Kroh UF; Lennartz H; Edwards DJ; Stoeckel K
J Clin Pharmacol; 1996 Dec; 36(12):1114-9. PubMed ID: 9013367
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin clearance during modeled continuous renal replacement therapy.
Churchwell MD; Pasko DA; Mueller BA
Blood Purif; 2006; 24(5-6):548-54. PubMed ID: 17124423
[TBL] [Abstract][Full Text] [Related]
13. A comparison of solute clearance during continuous hemofiltration, hemodiafiltration, and hemodialysis using a polysulfone hemofilter.
Reeves JH; Butt WW
ASAIO J; 1995; 41(1):100-4. PubMed ID: 7727810
[TBL] [Abstract][Full Text] [Related]
14. [The effects of dialysate and ultrafiltration flow rate on solute clearance during continuous renal replacement therapy].
Gong D; Ji D; Xie H; Xu B; Liu Y; Li L
Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):183-6. PubMed ID: 11798577
[TBL] [Abstract][Full Text] [Related]
15. A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system.
Jeffrey RF; Khan AA; Prabhu P; Todd N; Goutcher E; Will EJ; Davison AM
Artif Organs; 1994 Jun; 18(6):425-8. PubMed ID: 8060251
[TBL] [Abstract][Full Text] [Related]
16. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
Isla A; Gascón AR; Maynar J; Arzuaga A; Sánchez-Izquierdo JA; Pedraz JL
Chemotherapy; 2007; 53(3):194-201. PubMed ID: 17356270
[TBL] [Abstract][Full Text] [Related]
17. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.
Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Sagripanti S; Manini P; Andreoli R; Cabassi A
Crit Care Med; 2004 Dec; 32(12):2437-42. PubMed ID: 15599148
[TBL] [Abstract][Full Text] [Related]
18. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient.
Arzuaga A; Isla A; Gascón AR; Maynar J; Corral E; Pedraz JL
Blood Purif; 2006; 24(4):347-54. PubMed ID: 16645266
[TBL] [Abstract][Full Text] [Related]
19. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration.
Meyer TW; Walther JL; Pagtalunan ME; Martinez AW; Torkamani A; Fong PD; Recht NS; Robertson CR; Hostetter TH
Kidney Int; 2005 Aug; 68(2):867-77. PubMed ID: 16014068
[TBL] [Abstract][Full Text] [Related]
20. Continuous venovenous hemodialysis in a neonate model: a two-pump system.
Jouvet P; Colomer S; Jugie M; Meftali Y; Vassault A; Man NK
Crit Care Med; 1998 Jan; 26(1):115-9. PubMed ID: 9428552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
